Internal medicine

Prasugrel

Disease

Myocardial infarction

Family medicine

Political science

Intensive care medicine

China

Antithrombotic

Clopidogrel

Position statement

P2Y12

Ticagrelor

East Asia

Fibrinolytic agent

Medicine

Thrombosis and Haemostasis

East Asian patients have reduced anti-ischemic benefits and increased bleeding risk during antithrombotic therapies compared with Caucasian patients. As potent P2Y12 receptor inhibitors (e.g., ticagrelor and prasugrel) and direct oral anticoagulants are commonly used in current daily practice, the unique risk–benefit trade-off in East Asians has been a topic of emerging interest. In this article, we propose updated evidence and future directions of antithrombotic treatment in East Asian patients.

The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease